Ireland Pharmaceuticals & Healthcare Q4 2018
Despite the improved outlook for pharmaceutical consumption rates relative to the previous five years, Ireland’s smallmarket size by regional standards, together with cost control measures targeting the sector, will continue to limit the country’sattractiveness to drugmakers. We highlight upside risks to our forecasts dependent upon the success of the implementation of thehealth system reform. More broadly, the significant dependence of the Irish economy on a limited number of large multinationalsposes risks to overall market trends under an uncertain global trade environment. On the upside, the increasing prospect a'soft' Brexit bodes well for the Irish economy, supporting our sector market growth headlines.